ArticleParasites, hosts and diseases2026
Acanthamoeba profilin as a novel airway allergen with diverse sensitization patterns including pollen cross-reactivity.
Article in Parasites, hosts and diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Profilins are ubiquitous pan-allergens responsible for cross-reactivity between pollens and plant foods. While we previously demonstrated that recombinant Acanthamoeba profilin (rAc-PF) drives allergic airway inflammation via Th2/Th17 pathways in murine models, its clinical relevance in human allergic disease remains unclear. This study investigated rAc-PF as a novel inhalant allergen and its immunological impact on patients with allergic airway diseases. A total of 176 patients with allergic airway diseases underwent skin prick tests with rAc-PF and a standard panel of 55 common aeroallergens. Acanthamoeba-specific and rAc-PF-specific serum IgE levels were quantified using ELISA. To elucidate immune mechanisms, peripheral blood mononuclear cells from atopic asthma patients were stimulated with rAc-PF, and Th2/Th17 cytokine production was analyzed. Thirteen patients (7.4%) showed positive skin prick tests reactions to rAc-PF. This sensitization was significantly associated with tree, grass, and weed pollens, indicating a pan-allergen characteristic due to high cross-reactivity. Notably, one patient sensitized to rAc-PF reacted to no other common inhalants, suggesting rAc-PF as a unique causative agent. Patients exhibited significantly elevated levels of serum Acanthamoeba-specific and rAc-PF-specific IgE compared to healthy controls. Furthermore, rAc-PF stimulation of peripheral blood mononuclear cells from asthmatic patients induced robust production of IL-4, IL-5, IL-13, and IL-17A in humans. rAc-PF is identified as a novel allergen capable of inducing IgE-mediated sensitization and mixed Th2/Th17 responses. The strong association with pollen sensitization supports its role as an environmental pan-allergen. Therefore, rAc-PF should be considered a clinically relevant diagnostic target, especially in patients with polysensitization or unidentified triggers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.